• News
  • Cardio-Metabolic and Renal Diseases

Insights from the CLEAR Outcomes trial on MASLD and heart health

At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR Outcomes trial. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...

By: Toni Kovandjieva
  • News
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Metabolic dysfunction associated steatotic liver disease and the heart

Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...

By: Sanne-Lotte van Barneveld
  • Cardio-Metabolic and Renal Diseases

Webinar – Getting GRIP on MASH after LITMUS

On March 12th, we organised the webinar: Getting GRIP on MASH after LITMUSDuring this webinar, our speaker and hosts explored the following topics:The usefulness of noninvasive diagnostic methods depends on the prevalence of the disease ...

  • Webinars
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Webinar: Lifestyle Interventions in NAFLD/NASH

On the 19th of September, we presented the 9th webinar of our NASH Webinar Series. During this webinar, speaker Professor Zelber-Sagi explored the relationship between diet and NAFLD, emphasizing that diet not only causes NAFLD but can also serve ...

Download

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn